| Network‐based approaches in drug discovery and early development JM Harrold, M Ramanathan, DE Mager Clinical Pharmacology & Therapeutics 94 (6), 651-658, 2013 | 99 | 2013 |
| Clinically relevant cancer chemotherapy dose scheduling via mixed-integer optimization JM Harrold, RS Parker Computers & Chemical Engineering 33 (12), 2042-2054, 2009 | 83 | 2009 |
| Semi‐mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer VL Chudasama, F Schaedeli Stark, JM Harrold, J Tibbitts, SR Girish, ... Clinical Pharmacology & Therapeutics 92 (4), 520-527, 2012 | 53 | 2012 |
| Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions Y Vugmeyster, J Harrold, X Xu The AAPS journal 14, 714-727, 2012 | 52 | 2012 |
| Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons L Kagan, AK Abraham, JM Harrold, DE Mager Pharmaceutical research 27, 920-932, 2010 | 49 | 2010 |
| GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys SC Lu, M Chen, L Atangan, EA Killion, R Komorowski, Y Cheng, ... Cell Reports Medicine 2 (5), 2021 | 47 | 2021 |
| A Multiscale Model of Interleukin‐6–Mediated Immune Regulation in Crohn's Disease and Its Application in Drug Discovery and Development G Dwivedi, L Fitz, M Hegen, SW Martin, J Harrold, A Heatherington, C Li CPT: Pharmacometrics & Systems Pharmacology 3 (1), 1-9, 2014 | 37 | 2014 |
| Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics JM Harrold, RM Straubinger, DE Mager Cancer research 72 (7), 1632-1641, 2012 | 34 | 2012 |
| Disposition of human recombinant lubricin in naive rats and in a rat model of post-traumatic arthritis after intra-articular or intravenous administration Y Vugmeyster, Q Wang, X Xu, J Harrold, D Daugusta, J Li, R Zollner, ... The AAPS journal 14, 97-104, 2012 | 31 | 2012 |
| Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model R Zhou, RV Mazurchuk, JH Tamburlin, JM Harrold, DE Mager, ... Journal of Pharmacology and Experimental Therapeutics 332 (2), 479-488, 2010 | 26 | 2010 |
| Model-based design of cancer chemotherapy treatment schedules JM Harrold University of Pittsburgh, 2005 | 26 | 2005 |
| Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies VL Chudasama, A Zutshi, P Singh, AK Abraham, DE Mager, JM Harrold Journal of pharmacokinetics and pharmacodynamics 42, 1-18, 2015 | 25 | 2015 |
| Pharmacokinetic–pharmacodynamic modelling of neutrophil response to G‐CSF in healthy subjects and patients with chemotherapy‐induced neutropenia M Melhem, I Delor, JJ Pérez‐Ruixo, J Harrold, A Chow, L Wu, P Jacqmin British Journal of Clinical Pharmacology 84 (5), 911-925, 2018 | 24 | 2018 |
| Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling A Tiwari, AK Abraham, JM Harrold, A Zutshi, P Singh The AAPS journal 19, 510-519, 2017 | 17 | 2017 |
| Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment JM Harrold, AK Abraham Journal of pharmacokinetics and pharmacodynamics 41, 141-151, 2014 | 14 | 2014 |
| An MILP approach to cancer chemotherapy dose regime design JM Harrold, RS Parker Proceedings of the 2004 American Control Conference 1, 969-974, 2004 | 11 | 2004 |
| Prediction of survival benefit of filgrastim in adult and pediatric patients with acute radiation syndrome J Harrold, PO Gisleskog, JJ Perez‐Ruixo, I Delor, A Chow, P Jacqmin, ... Clinical and Translational Science 13 (4), 807-817, 2020 | 9 | 2020 |
| Navigating between right, wrong, and relevant: the use of mathematical modeling in preclinical decision making A Kondic, D Bottino, J Harrold, JD Kearns, CJ Musante, A Odinecs, ... Frontiers in pharmacology 13, 860881, 2022 | 8 | 2022 |
| Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer JM Bailis, P Lutterbuese, O Thomas, K Locher, J Harrold, M Boyle, J Wahl, ... Cancer Research 80 (16_Supplement), 3364-3364, 2020 | 8 | 2020 |
| A cell-level model of pharmacodynamics-mediated drug disposition W Krzyzanski, JM Harrold, LS Wu, JJ Perez-Ruixo Journal of pharmacokinetics and pharmacodynamics 43, 513-527, 2016 | 7 | 2016 |
Anson AbrahamPrincipal Scientist - Merck & Co., Inc.Dirección de correo verificada de merck.com
